Hyperuricaemia - febuxostat: review proposal - August 2011
Review of NICE Technology Appraisal Guidance No. TA164; Febuxostat for the management of hyperuricaemia in people with gout
Proposal to move guidance to the static list
As you may be aware the planned date for review of the above guidance is August 2011.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
The new clinical evidence that has been published since TA164 was issued is consistent with the conclusions by the Appraisal Committee on the clinical effectiveness of febuxostat. There has been no change to the price of febuxostat, and no information is available about any changes to the marketing authorisation or any new or ongoing trials of the effectiveness of febuxostat. Based on this information it is proposed that the guidance is placed on the static list.
Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 10 August 2011